Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

NSCLC 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × rezivertinib × Thoracic × Clear all
NCT03866499 2024-08-07

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Beta Pharma, Inc.

Phase 3 Active not recruiting
369 enrolled
Thoracic

NSCLC

NCT03812809 2022-05-19

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Beta Pharma, Inc.

Phase 2 Completed
226 enrolled
Thoracic

NSCLC

NCT03386955 2022-05-16

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Beta Pharma, Inc.

Phase 1/2 Completed
215 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡